PHATHOM PHARMACEUTICALS INC (PHAT) Forecast, Price Target & Analyst Ratings

NASDAQ:PHAT • US71722W1071

Current stock price

13.07 USD
-0.4 (-2.97%)
Last:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for PHATHOM PHARMACEUTICALS INC (PHAT).

Forecast Snapshot

Consensus Price Target

Price Target
$24.17
+ 84.96% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
Apr 29, 2026
Period
Q1 / 2026
EPS Estimate
-$0.31
Revenue Estimate
60.029M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
84.71%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$24.17
Upside
+ 84.96%
From current price of $13.07 to mean target of $24.17, Based on 17 analyst forecasts
Low
$13.13
Median
$26.01
High
$30.45

Price Target Revisions

1 Month
3.49%
3 Months
3.49%

Price Target Summary

17 Wall Street analysts provided a forecast for the next 12 months for PHAT. The average price target is 24.17 USD. This implies a price increase of 84.96% is expected in the next year compared to the current price of 13.07.
The average price target has been revised upward by 3.49% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

PHAT Current Analyst RatingPHAT Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6 8

Analyst Ratings History

PHAT Historical Analyst RatingsPHAT Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 5 10 15

Analyst Ratings Consensus

ChartMill Buy Consensus
84.71%
PHAT was analyzed by 17 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about PHAT.
In the previous month the buy percentage consensus was at a similar level.
PHAT was analyzed by 17 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-03-27BarclaysUpgrade Equal-Weight -> Overweight
2026-02-27GuggenheimMaintains Buy -> Buy
2025-12-09BarclaysInitiate Equal-Weight
2025-10-31HC Wainwright & Co.Maintains Buy -> Buy
2025-06-09Craig-HallumMaintains Buy -> Buy
2025-06-09HC Wainwright & Co.Reiterate Buy -> Buy
2025-06-06NeedhamMaintains Buy -> Buy
2025-05-02GuggenheimMaintains Buy -> Buy
2025-05-02Goldman SachsMaintains Neutral -> Neutral
2025-05-02HC Wainwright & Co.Maintains Buy -> Buy
2025-04-21NeedhamReiterate Buy -> Buy
2025-04-17Goldman SachsMaintains Neutral -> Neutral
2025-04-09NeedhamReiterate Buy -> Buy
2025-04-02GuggenheimReiterate Buy -> Buy
2025-04-02NeedhamReiterate Buy -> Buy
2025-03-10Goldman SachsMaintains Neutral -> Neutral
2025-03-07HC Wainwright & Co.Reiterate Buy -> Buy
2025-03-06NeedhamReiterate Buy -> Buy
2025-01-10NeedhamReiterate Buy -> Buy
2024-12-12HC Wainwright & Co.Reiterate Buy -> Buy
2024-12-11NeedhamReiterate Buy -> Buy
2024-09-13NeedhamReiterate Buy -> Buy
2024-09-06NeedhamReiterate Buy -> Buy
2024-08-30NeedhamReiterate Buy -> Buy
2024-08-23NeedhamReiterate Buy -> Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
Apr 29, 2026
Period
Q1 / 2026
EPS Estimate
-$0.31
Revenue Estimate
60.029M
Revenue Q2Q
110.49%
EPS Q2Q
76.09%
Number of Analysts
11

Next Earnings Revisions

Revenue (1 Month)
-0.24%
Revenue (3 Months)
0.30%
EPS (1 Month)
5.70%
EPS (3 Months)
25.39%

Next Earnings Summary

PHAT is expected to report earnings on 4/29/2026. The consensus EPS estimate for the next earnings is -0.31 USD and the consensus revenue estimate is 60.03M USD.
The next earnings revenue estimate has been revised upward by 0.3% in the past 3 months.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
PHAT revenue by date.PHAT revenue by date.
682K55.252M
8,001.47%		175.11M
216.93%		338.04M
93.04%		537.19M
58.91%		759.56M
41.40%		909.46M
19.74%		1.037B
14.02%		1.181B
13.89%		1.278B
8.21%		892.16M
-30.19%
EBITDA
YoY % growth
PHAT ebitda by date.PHAT ebitda by date.
-166.737M
2.96%		-276.672M
-65.93%		-159.353M
42.40%		30.786M
119.32%		135.26M
339.36%		360.03M
166.18%		481.59M
33.76%		587.39M
21.97%		679.94M
15.76%		756.12M
11.20%		N/A
EBIT
YoY % growth
PHAT ebit by date.PHAT ebit by date.
-167.312M
2.97%		-277.467M
-65.84%		-159.986M
42.34%		2.666M
101.67%		164.11M
6,055.66%		341.54M
108.12%		451.92M
32.32%		546.52M
20.93%		665.2M
21.72%		734.57M
10.43%		476.62M
-35.12%
Operating Margin
PHAT operating margin by date.PHAT operating margin by date.
-24,532.55%-502.18%-91.36%0.79%30.55%44.97%49.69%52.70%56.33%57.48%53.42%
EPS
YoY % growth
PHAT eps by date.PHAT eps by date.
-3.88
23.17%		-5.35
-37.89%		-3.06
42.80%		-0.59
80.67%		1.16
296.17%		2.89
148.86%		4.47
54.93%		5.65
26.29%		7.43
31.50%		8.47
14.00%		7.99
-5.72%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27 Q1 / 28 Q2 / 28 Q3 / 28 Q4 / 28
EPS
Q2Q % growth		-0.31
76.09%		-0.20
80.73%		-0.07
82.05%		0.06
121.10%		0.08
124.42%		0.18
190.73%		0.36
592.10%		0.59
866.67%		0.32
313.33%		0.52
183.33%		0.71
97.18%		0.94
58.62%
Revenue
Q2Q % growth		60.029M
110.49%		76.009M
92.41%		92.999M
87.86%		110.11M
91.25%		107.81M
79.60%		120.97M
59.15%		139.94M
50.47%		166.82M
51.50%		148.21M
37.47%		170.54M
40.98%		196.86M
40.67%		226.24M
35.62%
EBITDA
Q2Q % growth		-8.295M
89.46%		2.123M
103.56%		13.588M
192.02%		20.865M
494.05%		3.876M
146.73%		15.402M
625.48%		23.154M
70.40%		31.008M
48.61%		N/AN/AN/AN/A
EBIT
Q2Q % growth		-12.156M
84.59%		-4.587M
92.35%		8.225M
153.86%		17.422M
393.89%		16.32M
234.25%		25.959M
665.91%		40.494M
392.33%		61.404M
252.45%		42.126M
158.13%		58.344M
124.75%		77.724M
91.94%		100.16M
63.12%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

PHAT Yearly Revenue VS EstimatesPHAT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
PHAT Yearly EPS VS EstimatesPHAT Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5 -10

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
43.32%
EPS Next 5 Year
30.92%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
62.25%
Revenue Next 5 Year
42.28%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
60.82%
EBIT Next 5 Year
40.75%
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

PHATHOM PHARMACEUTICALS INC / PHAT Forecast FAQ

What is the price target for PHAT stock?

17 analysts have analysed PHAT and the average price target is 24.17 USD. This implies a price increase of 84.96% is expected in the next year compared to the current price of 13.07.

What is the next earnings date for PHAT stock?

PHATHOM PHARMACEUTICALS INC (PHAT) will report earnings on 2026-04-29.

What are the consensus estimates for PHAT stock next earnings?

The consensus EPS estimate for the next earnings of PHATHOM PHARMACEUTICALS INC (PHAT) is -0.31 USD and the consensus revenue estimate is 60.03M USD.

What is the expected long term growth rate for PHATHOM PHARMACEUTICALS INC (PHAT)?

The expected long term growth rate for PHATHOM PHARMACEUTICALS INC (PHAT) is 62.25%.